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Abstract 
Early life-stage bioassays have been used as an alternative to short-term adult toxicity tests since they 
are cost-effective. A single couple can produce hundreds or thousands of embryos and hence can be 
used as a simple high-throughput approach in toxicity studies. In the present study, zebrafish and sea 
urchin embryo bioassays were used to test the toxicity of four pharmaceuticals belonging to different 
therapeutic classes: diclofenac, propranolol, simvastatin and sertraline. Simvastatin was the most toxic 
tested compound for zebrafish embryo, followed by diclofenac. Sertraline was the most toxic drug to 
sea urchin embryos, inducing development abnormalities at the ng/L range. Overall, our results 
highlight the potential of sea urchin embryo bioassay as a promising and sensitive approach for the 
high-throughput methods to test the toxicity of new chemicals, including pharmaceuticals, and identify 
several drugs that should go through more detailed toxicity assays. 
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1. Introduction 
In the past decade, the presence of emerging contaminants in the aquatic environment has raised 
considerable concern (Bossus et al., 2014). Pharmaceuticals are a group of emerging contaminants that 
have been recently detected in the water compartment at low concentrations in the ng/L or µg/L range 
(Lapworth et al., 2012). Their occurrence raises concern not only for human health but also for wildlife. 
In fact, although human exposure to contaminated water occurs in discontinuous process, aquatic 
ecosystems are continually exposed to this type of chemicals and several studies have already identified 
different pharmaceuticals in concentrations that are likely to induce adverse effects in aquatic 
organisms (Fent et al., 2006). Pharmaceuticals can enter into the aquatic environment through point 
and non-point sources and for several classes the Wastewater Treatments Plants (WWTPs) cannot 
ensure complete removal, and therefore WWTPs effluents may still have significant concentrations of 
some pharmaceuticals (Fent et al., 2006). One of the best characterized examples of the toxic potential 
of pharmaceuticals is the synthetic estrogen ethynilestradiol (EE2). At the low ng/L range (0.1–5 ng/L), 
EE2 impacts ecologically relevant endpoints in fish such as behavior, embryonic development, 
reproduction and sex ratio (Micael et al., 2007, Soares et al., 2009, Santos et al., 2010 and Soares et 
al., 2012). Therefore, this example calls our attention to other bioactive compounds that are 
ubiquitously present at low concentrations, and for which no detailed ecotoxicological evaluation has 
been carried out. 
Due to restrict regulatory approval processes to evaluate the pharmaceutical effects and efficacy, these 
compounds have a substantial margin of safety for humans and are better characterized than many 
others environmental contaminants (World Health Organization, 2011). However, there is still a 
serious lack of information about the effects in non-target species, particularly considering chronic 
exposure, sensitive development stages, or possible effects resulting from chemical mixtures 
(Lapworth et al., 2012). In fact, even if pharmaceuticals have been designed to be bioactive in humans, 
it is possible that aquatic organisms that share conserved signaling pathways experience the same 
pharmacodynamic effects (Fent et al., 2006). 
Hence, we aimed here at improving our knowledge on the ecotoxicological effects of selected 
pharmaceutical. Chemical selection in the present study was based on data from literature, taking into 
account their relevance, either by prescription amount, environmental concentrations and effects 
already reported or existing gaps in their ecotoxicity. Thus, four compounds were chosen, belonging 
to different classes: non-steroidal anti-inflamatory drugs (Diclofenac), β-blockers (Propranolol), 
antidepressants (Sertraline) and hypolimidemic (Simvastatin). Diclofenac (DCF) is a common 
prescribed non-steroidal anti-inflamatory drug (NSAID) used in treatments of inflammation, high 
temperature and for some rheumatologic diseases. Propranolol (PROP) is a commonly used β-blocker 
and inhibits β-1 and β-2 adrenergic receptors. β-blockers act by inhibiting β-adrenergic receptors 
present in heart, which leads to a decrease of heart beating and contractility (Santos et al., 
2010 and INFARMED – Prontuário terapêutico online. 2010. Retrieved on 14.07.14, from 
http://www.infarmed.pt/prontuario/prontuario_terapeutico.pdf.). Sertraline (SER) is a widely 
prescribed antidepressant belonging to the selective serotonin reuptake inhibitors (SSRIs) (Santos et 
al., 2010 and Park et al., 2012). Simvastatin (SIMV) is a statin with hypolipidemic properties; it is used 
to decrease cholesterol concentration in blood plasma, reducing mortality and morbidity from coronary 
heart diseases (Fent et al., 2006 and Santos et al., 2010). 
The overall aim of the present work was to contribute for the ecotoxicological risk assessment of the 
pharmaceuticals diclofenac, propranolol, sertraline and simvastatin in aquatic environments. This was 
approached using as model bioassays the embryonic development of representatives of a vertebrate 
and an invertebrate group, i.e., the teleost fish zebrafish (Danio rerio) and the equinoderm, sea urchin 
(Paracentrotus lividus). Both bioassays have been extensively validated for the screening of priority 
pollutants, display a high sensitivity, are cost-effective and allow a high-throughput screening 
approach. 
2. Material and methods 
2.1. Chemicals 
Diclofenac, Propranolol, Sertraline and Simvastatin were purchased from Sigma-Aldrich®, Potassium 
chloride (CAS 7447-40-7, 99.0%), Calcium chloride (CAS 10043-52-4, 93.0%), Magnesium chloride 
hexahydrate (CAS 7791-18-6, 99.9%), Magnesium sulfate (CAS 7487-88-9, 99.5%) were purchased 
from Sigma-Aldrich. Sodium chloride (CAS 7647-14-5, 99.5%), Sodium bicarbonate (CAS 144-55-8) 
and dimethylsulfoxide (DMSO) were purchased from Merck. 
2.2. Species selection 
Zebrafish (Danio rerio) is a species increasingly used in several fields of research due to its small size, 
short life-cycle, ease of maintenance and reproduction in laboratory conditions, and full genome 
sequence available. Furthermore, eggs are translucent which makes easier the monitoring of embryo 
development ( Soares et al., 2009). 
The sea-urchin (Paracentrotus lividus) is an invertebrate used in ecotoxicological studies due to their 
ease of obtaining, ecological relevance and reduced development time (48 h) ( Bellas et al., 2005). 
2.3. Fertilization and embryos collection 
2.3.1. Zebrafish 
Adult zebrafish were kept at 28 °C and 14:10 h (light/dark) cycle as described by Soares et al. (2009). 
All experiments conducted in this study were carried out at Biotério de Organismos Aquáticos (BOGA, 
CIIMAR) aquatic animal facilities, in accordance to the guidelines of the Directorate-General of 
Veterinary of Portugal (decree law 113/2013), based on the European directive of animal welfare 
2010/63/EU. 
For spawning, adult males and females (2:1) were placed in breeding tanks overnight. At the following 
day, ovulation and fertilization were stimulated by the beginning of light period (Soares et al., 2009). 
2.3.2. Sea urchin 
Sea urchin were collected in a clean area in the north of Portugal, Granja, Vila Nova de Gaia (N41° 2′ 
26,18″, W -8° 39′ 2,24″), and transported to the laboratory in a portable icebox containing seawater. 
After arrival at the laboratory, animals were dissected, eggs and sperm directly pipetted from the 
freshly gonads of a single pair of adult individuals and assessed for their quality. Eggs were suspended 
in artificial sea water (90 ml). Artificial seawater was prepared according to Zaroogian et al. (1999) 
using Potassium chloride (0.67 g/L), Calcium chloride (1.36 g/L), Magnesium chloride hexahydrate 
(4.66 g/L), Magnesium sulfate (2.04 g/L), Sodium chloride (24.6 g/L) and Sodium bicarbonate 
(0.39 g/L). 
A few microliters of undiluted sperm were added to the egg suspension and stirred to allow fertilization. 
The success of fertilization, indicated by the presence of a fertilization membrane, was evaluated under 
microscope. Toxicity tests were performed when the fertilization rate was above 97%. 
2.4. Experimental design and embryo bioassays 
2.4.1. Experimental solutions 
Experimental concentrations of selected compounds were chosen based on the data from the literature, 
with 10× dilutions, in order to cover a wide range of concentrations, including pharmacological and 
environmental relevant concentrations. For the sea urchin embryo bioassay, after a first assay with 10× 
serial dilutions (Fig. 1; A, C, E, G), a 2.5× serial dilutions, with lower test concentrations (Fig. 1; B, 
D, F, H) were carried out. In order to assure reproducibility among assays, the lowest tested 





Eight replicates for a total of six treatments conditions were set up for zebrafish: an experimental control, 
a solvent control (DMSO) and four concentrations of each chemical. For sea urchin we used a similar 
experimental design, but serial dilutions with seven concentrations were tested (Lammer et al., 2009). 
Stock solutions of each compound were prepared by dissolving Simvastatin, Sertraline, Diclofenac and 
Propranolol in Dimethylsulfoxide (DMSO). The experimental solutions were obtained by diluting the stock 
solutions in artificial seawater (Sea urchin assays) or in freshwater (Zebrafish assays). All solutions were 
prepared in order to have a final DMSO concentration of 0.01%. 
2.4.2. Zebrafish 
The static-water renewal toxicological tests with zebrafish were performed according to OECD guidelines 
(Organization for Economic Co-operation and Development (OECD), 1998). After embryos observation 
using a magnifying glass, 10 fertilized eggs were selected and randomly allocated into 24-wells plates filled 
with 2 mL of freshly prepared solutions and controls. The 24-wells plates were incubated at 26.5 °C during 
80 h and under the same photoperiod conditions as the zebrafish stock. The medium was renewed daily in 
order to maintain oxygen and toxic nominal concentrations constants during the assay and to remove fungi 
or other organisms that could develop in the well. 
The effects of exposure have been assessed by randomly choosing 6 embryos per well (including controls) 
at 3 distinct periods, representative of important steps of embryo development: gastrula period (65–75% 
epiboly stage), pharyngula period (prim15–16) and larval stage (protruding-mouth) at 8, 32 and 80 h post 
fertilization (hpf), respectively. Non-viable embryos were removed at each observation time. 
Morphological abnormalities on head, tail, eyes or yolk-sac, pericardial edema, abnormal cell growth and 
75% of epiboly stage were rated as present or absent in accordance with previous validated protocols 
(Lammer et al., 2009, Organization for Economic Co-operation and Development (OECD), 1998 and Pinho 
et al., 2013). To increase statistical power, all scored abnormalities were grouped to determine the 
percentage of total abnormalities. The analysis was performed using a stereoscopic microscope (Nikon 
SMZ-1000) with a maximum magnification of 80 times. 
2.4.3. SEA urchin 
Within 30 min after fertilization, fertilized eggs of sea urchin were placed in 24-well plates with 3 mL of 
freshly test solution in a concentration of 20 eggs/mL. The 24-wells plates were isolated with parafilm and 
embryos were incubated at 20 °C in dark for 48 h. At the end of exposure time, embryos were fixed by 
adding three drops of 37% formaldehyde and directly observed under an inverted microscope. 
Embryogenesis success was recorded by applying two toxicity criteria: larvae length and morphological 
abnormalities of individuals. The number of analyzed individuals for the two criteria was based on Saco-
Álvarez et al. (2010). Hence, the maximum larvae length was measured in 15 individuals per well in pluteus 
stage (120 individuals per treatment), defined as the distance between the apex and the end of the post-oral 
arm. Larvae were considered normal by the pyramid shape and four fully separated arms (Saco-Álvarez et 
al., 2010). In order to evaluate morphological effects resulting from individual exposures, 20 individuals 
per well (160 individuals per treatment) were analyzed. Abnormal larvae were counted separately as 
undeveloped organisms or malformed larvae. Undeveloped organisms included all the embryos which 
development suffers a delay or a blockage at early stages, i.e., fertilized eggs, 2-cell stage and morula, 
gastrula and prepluteus stage All changes to the normal development at 48 hpf were recorded and presented 
as abnormal larvae; this included crossed tip, separated tip, folded tip, fused arms, deformed arms, abnormal 
arms orientation, absence or asymmetric arms (Fig. 1S, supplementary information). 
Observations were performed with a Nikon Eclipse 5100T inverted microscope equipped with a Nikon D5-
Fi2 digital cam. Larvae length was measured using NIS-Elements version 4.13 image acquisition software. 
2.5. Statistical analysis 
Statistical analysis was performed with SPSS software (version 21.0). 
All data were first tested for normality and homogeneity of variances using Kolmogorov–Smirnov and 
Levene’s Test. If these assumptions were met, differences between treatments were tested for significance 
by means of one-way factorial ANOVA followed by Newman–Keuls multiple comparison test to compare 
the control groups and each of the exposed groups. If the homogeneity and normality were not met even 
after data transformation, data were analyzed using a non-parametric test – Kruskal–Wallis, followed by a 
multiple comparison rank test. Differences were considered significant for p<0.05. Values were expressed 
as the mean±standard error (SE). 
D. rerio statistical analysis was carried out at 80 hpf as well as to the 8 hpf endpoints abnormal cell growth 
and 75% of epiboly stage. Control and solvent control were grouped for both species bioassay, when no 
significant differences between them were detected. 
3. Results 
3.1. Diclofenac 
Zebrafish embryos exposed to diclofenac revealed significant alterations (p<0.05) in hatching rate, 
abnormal cell growth, 75% epiboly-stage and yolk-sac abnormalities (Table 1). Hatching rate significantly 
decreased (p<0.05) in embryos exposed to 12.5 mg/L when compared with other treatments. An exposure 
to 1.25 and 12.5 mg/L of diclofenac resulted in a significant decrease in the percentage of zebrafish embryos 
at 75% epiboly stage. A significantly increase (p<0.05) in the percentage of embryos with abnormal cell 
growth at the two highest concentrations was also observed in our study. The percentage of embryos with 
yolk-sac abnormalities was also significantly increased (p<0.05) after exposure to the highest concentration 
of diclofenac. For the remaining endpoints, exposure to diclofenac did not cause significant alterations in 
zebrafish embryos (p>0.05). 
 
  
An exposure of sea urchin embryos to diclofenac resulted in a significant decrease of larval length and an 
increase in the percentage of abnormal development (p<0.05) for concentrations equal or higher than 
12.5 µg/L ( Fig. 1A and B). 
3.2. Propranolol 
In this study, zebrafish embryos exposed to the highest tested concentration of propranolol had an increased 
mortality rate between 32 and 80 hpf and all embryos were dead at the end of the assay (Table 1). For the 
remaining criteria significant departure from control were not recorded (p>0.05). However, an exposure to 
125 µg/L of propranolol induced a significant increase (p<0.05) in the percentage of total abnormalities 
when compared to controls and 12.5 µg/L exposure group. 
Sea urchin embryos exposed to propranolol were significantly affected (Fig. 1C and D). All embryos 
exposed to 1.25 and 12.5 mg/L of propranolol were in morula stage at the end of the assay, and therefore 
no measurements were performed for these two exposure groups. An exposure to concentrations equal or 
higher than 12.5 µg/L of propranolol resulted in a statistically significant decrease of larval length (p<0.05). 
However, an exposure to propranolol concentrations equal or higher than 5 µg/L resulted in a statistically 
significant increase in the percentage of abnormal organisms (p<0.05). 
3.3. Sertraline 
In the present study exposure to 10 mg/L of sertraline led to the mortality of all zebrafish embryos at 80 hpf. 
No significant differences in cumulative mortality rate (p>0.05) were observed for the other exposure 
groups in comparison with control groups ( Table 1). Considering the sub-lethal parameters, a significant 
decrease (p<0.05) in the percentage of zebrafish embryos at 75% epiboly-stage was observed in the groups 
exposed to the highest concentration. At 32 hpf, this exposure group showed a higher percentage of embryos 
with tail, yolk-sac and head abnormalities. These effects, associated with the development delay observed 
at 8 hpf, explain the mortality rate in the 10 mg/L exposure group at the end of the assay. We also observed 
a significantly increase (p<0.05) in the percentage of embryos with yolk-sac abnormalities at 100 µg/L 
when compared to controls and 10 µg/L exposure group. At the end of the assay, the percentage of total 
abnormalities in embryos did not differed significantly among groups (p>0.05). 
Sertraline significantly impacted sea urchin embryo development (Fig. 1E and F). An observation of 
10 mg/L exposed-embryos revealed fertilized eggs and embryos in the two-cell cleavage stage, and hence 
the embryonic development was arrested. All embryos exposed to 1 mg/L of sertraline were in morula stage 
at the end of the assay. For this reason, no measurements were performed for these two exposure groups. 
Larval length of 100 and 10 µg/L exposure groups was significantly lower than controls. Although no 
statistically significant changes were reported in larval length for exposures bellow 10 µg/L of sertraline, 
an exposure to concentrations equal or higher than 0.64 µg/L resulted in a statistically significant increase 
in the percentage of larvae with morphological abnormalities (p<0.05) compared to controls. 
3.4. Simvastatin 
In this study, simvastatin was the most toxic compound for zebrafish embryos. An exposure to 5 mg/L of 
simvastatin was lethal to all zebrafish embryos between 32 hpf and 80 hpf. Zebrafish embryos exposed to 
the highest tested concentration showed general body abnormalities at 32 hpf. These abnormalities led to 
death of all zebrafish embryos and no hatches were recorded at 80 hpf. An exposure of zebrafish embryos 
to 500 µg/L of simvastatin resulted in a statistically significant increase (p<0.05) in the percentage of 
embryos with eyes, tail and yolk-sac abnormalities and also pericardial edema at the end of the assay ( 
Table 1). 
Sea urchin embryos were also affected by exposure to simvastatin. At the end of the assay, an exposure to 
5 mg/L of simvastatin resulted in a significant delay in embryo development and no length recording were 
performed for this exposure group. A significant decrease (p<0.05) in larval length was recorded for 
concentrations equal or higher than 5 µg/L ( Fig. 1G and H). However, embryos exposed to concentration 
equal or higher than 2 µg/L showed also a significant increase (p<0.05) in the percentage of total 
abnormalities at the end of the assay, being this endpoint more sensitive than larval length. 
4. Discussion 
4.1. Diclofenac 
Diclofenac has received much attention on the past decade due to its effects in vulture populations in the 
Indian subcontinent (Oaks et al., 2004). Although this compound is not persistent, it is frequently detected 
in the environment due to its continuous released as well as a result of incomplete removal in WWTPs, 
inducing potential negatives effects in exposed organisms (Heberer et al., 2002 and Lee et al., 2011). 
The effects of diclofenac in zebrafish embryos in our study are similar to data reported in the literature 
(Brandhof and Montforts, 2010). The most sensitive endpoints were hatching rate, 75% epiboly-stage, 
abnormal cellular growth and yolk-sac abnormalities, which contributed to a significant increase of total 
abnormalities. Taking together our results for sea urchin embryos (LOEC of 12.5 µg/L) and the reported 
environmental concentrations of diclofenac of up to 3 µg/L in sewage, possible long-term effects in aquatic 
organisms cannot be disregarded (Heberer et al., 2002). 
4.2. Propranolol 
Propranolol is a β-blocker frequently detected in aquatic ecosystem (Ternes, 1998). As β-adrenergic 
receptors are also present in heart, hepatocytes and reproductive tissues of fish and other vertebrates, it is 
possible that these organisms can also be affected by β-blockers action (Nickerson et al., 2001). 
In a previous study performed by Fraysse et al. (2006), an higher percentage of zebrafish embryos exposed 
to propranolol showing pericardial edema and tail abnormalities were recorded at the highest tested 
concentration (108 µM). Fraysse et al. (2006) reported also an absence of hatched embryos at the end of 
the assay at the highest tested concentration, which is in agreement with our results. 
To the best of our knowledge, our study is the first to address the effects of propranolol in the embryonic 
development of sea urchin. The LOEC reported here for sea urchin (5 µg/L) and zebrafish development 
(125 µg/L) is in the range of environmental levels of propranolol (304 µg/L in seawage treatment plant 
outflow) (Ternes, 1998 and Roberts and Thomas, 2006), and hence a negative impact may occur in the most 
contaminated areas. 
4.3. Sertraline 
Several studies report SSRIs as disruptors of reproductive functions in fish, although some contradictory 
findings were reported and little is known about their effects (Bossus et al., 2014 and Park et al., 2012). As 
the cellular receptors of SSRIs are evolutionary conserved, aquatic organisms may experience similar 
responses or side effects to those reported for humans (Schultz et al., 2011). This is particularly important 
since the use of antidepressants increased over 60% in the past decade. Furthermore, this class of 
pharmaceuticals has been detected in coastal waters and estuaries, representing about 4% of the therapeutic 
drugs reported in the environment (Fent et al., 2006). According to IMS Health, sertraline was the second 
most prescribed psychiatric drug in U.S., during 2013 (Grohol, 2008). Moreover, few studies have 
investigated sertraline effects in initial stages of development. Nevertheless, based on some preliminary 
studies, sertraline seems to be the most toxic SSRIs, showing the higher bioconcentration factor and being 
the compound that contributes the most to the toxicity of SSRIs mixture (Bossus et al., 2014 and Styrishave 
et al., 2011). Schultz et al. (2011) evaluated the effects resulting from a 21D-exposure of male fathead 
minnows (Pimephales promelas) to several SSRIs at environmentally relevant concentrations. The authors 
reported a significant decrease of organism’s survival in the group exposed to 5.2 ng/L of sertraline. Fish 
exposed to 5.2 ng/L and 1.6 ng/L showed a sertraline brain concentration higher than suggested by water 
concentrations (0.06 ng/L and 0.023 ng/L, respectively). In our study, no effects were reported in zebrafish 
and sea urchin embryos at this concentration range. The most sensitive endpoints for zebrafish embryo 
exposure were cumulative mortality rate and 75%-epiboly stage and all tested concentrations induced a 
significant impact in the percentage of total abnormalities in sea urchin assay, which was a more sensitive 
endpoint than larval length. 
In a recent study, the amphipod Echinogammarus marinus was exposed to environmentally relevant 
concentrations of fluoxetine and sertraline from 0.001 to 0.1 µg/L ( Bossus et al., 2014). Significant 
differences were observed on velocity after 1 h-exposure to sertraline at 0.01 µg/L. Predicted Environmental 
Concentrations (PECs) of sertraline in Norwegian aquatic environments have been estimated at 170 ng/L, 
which is in the same range of the LOEC for sea urchin in our study (640 ng/L) ( Grung et al.). Similar to 
propranolol exposure, larval length endpoint was less sensitive than the percentage of abnormal sea urchin 
larvae. Taken together the findings of our study and others, and given the increasing usage of SSRIs, 
possible long-term effects in the most sensitive species are likely to occur. 
4.4. Simvastatin 
Only a few studies addressed the effects of simvastatin to aquatic animals and almost no information is 
available for early life-stages. In a study performed by Key et al. (2008), after exposure of 96 h to different 
concentrations of simvastatin, larval and adult grass shrimp (Palaemonetes pugio) showed a LC50 of 
1.118 mg/L and higher than 10 mg/L, respectively. In our study, all zebrafish embryos exposed to 
simvastatin at concentrations similar to the highest concentrations tested in Key et al. (2008) study died 
before the end of the assay. 
Ellesat et al. (2010) evaluated the effects of simvastatin and atorvastatin cytotoxicity in primary hepatocytes 
of O. mykiss exposed to concentrations ranging from 1 to 200 mg/L. The authors reported toxic effects in 
a dose–response manner which seemed to be related with the reducing of metabolic activity and membrane 
stability. In another study, the adults harpacticoid copepod Nitocra spinipes was exposed to simvastatin for 
96 h, which a LC50 of 810 µg/L ( Dahl et al., 2006). A significant decrease in development rate of N. 
spinipes was reported after exposure to simvastatin in a range of concentrations between 0.16 and 1.6 µg/L. 
These results were observed at the same range of effective concentrations that induced a decrease of larval 
length and an increase in the percentage of morphological abnormalities in sea urchin larvae in our study. 
Similar to the other selected compounds, total abnormalities was more sensitive for sea urchin assay than 
larval length endpoint. Recently Neuparth et al. (2014) observed a significant impact in the amphipod 
Gammarus locusta reproduction at predicted environmental concentrations, further stressing the sensitivity 
of several invertebrate taxa to simvastatin exposure. Although data on environmental concentration of 
simvastatin are very limited, recent PECs in Norwegian aquatic environments have been estimated at 
630 ng/L, which is in the same range of the LOEC recorded here for sea urchin (2 µg/L) ( Grung et al.). 
Furthermore, given that the generic of simvastatin was recently introduced in European countries, it is likely 
that environmental levels tend to increase, and hence might increase the risk of this pharmaceutical to the 
most sensitive taxa. 
5. Conclusions 
In conclusion, all tested compounds induced significant effects in embryonic and larval development of 
zebrafish and sea urchin, which indicates that the most sensitive taxa might be at risk. Considering the 
present findings and given that the toxicity data for sertraline and simvastatin are very limited, additional 
studies should be carried out involving other taxa and chronic exposures. 
In contrast to zebrafish embryo bioassays, there is a paucity of data on the use of sea urchin embryo 
bioassays in the toxicity screening of emerging pollutants. The results of this study indicates high sensitivity 
of sea urchin embryos to the tested pharmaceuticals, and suggest the combined use of zebrafish and sea 
urchin embryo bioassays in toxicological risk assessment of emerging pollutants. Overall, our study shows 
that early life-stages of aquatic animals are a promising approach for the increasing demand of high-
throughput methods to test the toxicity of new chemicals, including pharmaceuticals. 
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